SNDX Company Profile and Key Details

Q: Who are the executives of SNDX?

Sharon KlahreVice President of Investor Relations & CommunicationsDr. Peter Ordentlich B.Sc., Ph.D.Co-Founder & Chief Scientific OfficerDr. Briggs W. Morrison M.D.Pres, Head of R&D and DirectorDr. Ronald M. Evans Ph.D.Co-Founder, Advisor and Chair of Scientific Advisory BoardDr. Michael Downes Ph.D.Co-FounderDr. Briggs W. Morrison M.D., Ph.D.Pres, Head of R&D and DirectorMr. Michael A. Metzger M.B.A.Chief Executive Officer & DirectorDr. Anjali Ganguli Ph.D.Chief Bus. OfficerMr. Keith Alan Goldan CPAChief Financial Officer, Treasurer & Chief Accounting OfficerMr. Steve M. SabusChief Commercial OfficerMr. Luke J. AlbrechtSenior Vice President, Gen. Counsel & Sec.Dr. Catherine Madigan M.D.Chief Medical OfficerMr. Alexander NolteInterim Chief Financial Officer, Principal Accounting Officer & Treasurer

NASDAQ : SNDX

Syndax Pharmaceuticals

$19.76

-0.16-0.80%

At Close 4:00 PM

55.95

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Syndax Pharmaceuticals, Inc. (SNDX) stock declined over -0.80%, trading at $19.76 on NASDAQ, down from the previous close of $19.92. The stock opened at $19.67, fluctuating between $19.38 and $20.39 in the recent session.

Stock Snapshot

19.92

Prev. Close

1.75B

Market Cap

19.38

Day Low

-7.87

P/E Ratio

-2.51

EPS (TTM)

-2.21

Cash Flow per Share

19.67

Open

88.61M

Number of Shares

20.39

Day High

94.89%

Free Float in %

7.64

Book Value

1.48M

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Aug 06, 2026	19.61	20.39	19.38	19.76	1.48M
Aug 05, 2026	17.31	20.31	17.20	19.92	3.77M
Aug 04, 2026	19.56	19.85	19.00	19.08	2.01M
Aug 03, 2026	19.01	19.41	18.68	19.24	1.61M
Jul 31, 2026	19.37	19.50	18.64	19.05	1.21M
Jul 30, 2026	19.17	19.66	18.83	19.48	1.1M
Jul 29, 2026	19.74	19.89	18.85	19.22	1.75M
Jul 28, 2026	20.48	20.48	19.40	19.63	935.04K
Jul 27, 2026	21.09	21.57	20.50	20.52	1.1M
Jul 24, 2026	21.38	21.44	20.57	20.81	1.23M
Jul 23, 2026	21.80	21.88	21.17	21.21	1.31M
Jul 22, 2026	22.44	22.74	21.83	22.05	1.06M
Jul 21, 2026	22.37	22.72	22.10	22.64	1.19M
Jul 20, 2026	22.95	23.28	22.28	22.29	1.31M
Jul 17, 2026	22.34	23.45	22.24	22.80	1.06M
Jul 16, 2026	23.52	24.41	22.67	22.71	1.6M
Jul 15, 2026	23.96	24.20	23.26	23.52	2.28M
Jul 14, 2026	22.57	24.20	22.57	24.13	2.08M
Jul 13, 2026	23.21	23.33	22.26	22.89	1.42M
Jul 10, 2026	24.79	24.79	23.01	23.61	2.1M

Contact Details

New York City, NY 10017

United States

https://www.syndax.com 781 419 1400

About Company

Syndax Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm focused on developing innovative therapies for cancer. Among its leading investigational products are SNDX-5613, currently undergoing Phase 1/2 clinical assessment, which targets the Menin-mixed lineage leukemia 1 protein interaction for treating MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML). Another significant candidate is SNDX-6352, or axatilimab, a monoclonal antibody designed to block the colony stimulating factor 1 (CSF-1) receptor, intended for patients suffering from chronic graft versus host disease (cGVHD). The company is additionally progressing Entinostat. Syndax has also established strategic collaborations, including a research and development agreement with the National Cancer Institute, a clinical trial agreement with the Eastern Cooperative Oncology Group, and a license agreement with Kyowa Hakko Kirin Co., Ltd. Founded in 2005, Syndax Pharmaceuticals, Inc. maintains its corporate headquarters in Waltham, Massachusetts.

Stock Peers

ARGX

7.36+0.85%

argenx SE$875.30 REGN

3.53+0.46%

Regeneron Pharmaceuticals, Inc.$772.11 UTHR

13.93+2.68%

United Therapeutics Corporation$532.94 MDGL

-3.76-0.73%

Madrigal Pharmaceuticals, Inc.$510.36 VRTX

-0.8-0.17%

Vertex Pharmaceuticals Incorporated$484.03 PRAX

50.93+15.95%

Praxis Precision Medicines, Inc.$370.16 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 ONC

2.27+0.69%

BeOne Medicines AG$329.80 KRYS

-3.09-0.95%

Krystal Biotech, Inc.$322.69 LGND

-2.43-0.80%

Ligand Pharmaceuticals Incorporated$300.14

Company Overview

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) closed at $19.76 USD, losing -$0.16 (-0.80%) from the previous close of $19.92. The stock is currently mid-range between its 52-week high and low $12.10 and $25.59. With a market capitalization of about $1.75 billion, Syndax Pharmaceuticals, Inc. is classified as a small-cap and shows lower-than-market volatility (beta ~0.37). Key stats such as the average daily volume over the past year has been around 1.83 million shares, in line with its 52-week average. Headquartered in New York City, NY, Syndax Pharmaceuticals, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Michael A. Metzger, the company employs approximately 298 people and listed since March 02, 2016. Syndax Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm focused on developing innovative therapies for cancer.

Technical Performance

Short-term trend indicators are mixed aligned (SMA20 -0.07%, SMA50 -0.7%, SMA200 33.89%). The stock’s 14-day RSI is 50.57 (neutral), while the ATR of 0.91 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -9.06% below its high and over 140.91% above its low. Average 10-day trading volume of 1.66 million shares is below the 3-month average of 1.86 million, indicating normal recent market interest.

Valuation Metrics

Syndax Pharmaceuticals, Inc. trades at a P/E ratio of -7.8, slightly below the S&P 500 average, with a price-to-sales ratio of 6.91 and a price-to-book ratio of 115.82 reflecting a rich premium to book value. The P/FCF stands at -6.42, also above market averages. Compared to sector medians, Syndax Pharmaceuticals, Inc. P/S is trading rich, and the P/B is far higher than peers, underscoring the brand and earnings power premium investors assign to the stock.

Dividend & Fair Value

Syndax Pharmaceuticals, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.81. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

Syndax Pharmaceuticals, Inc. generated EPS of -$3.62 over the past year. Five-year average earnings growth is -15.16%. The latest quarter delivered EPS of -$0.55. The next quarter is forecast at -$0.58. Next year's EPS is expected at -$7.72. Analyst sentiment is bullish. Analyst rating data shows there are 7 Strong Buy ratings, 17 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $600.00 to $22.00. The high target offers 2936.44% upside. The low target suggests 11.34% downside. The mean target is $63.71. This offers 222.42% upside. Syndax Pharmaceuticals, Inc. earnings surprise history is a mixed track record. The quarter that ended August 04, 2026, missed forecasts by 22.86%. The prior quarter beat by -18.64%. Over the last six quarters, Apple has recorded several small beats. These include -5.77% in May 05, 2025.

Shareholding & Insider Activity

Syndax Pharmaceuticals, Inc. has 88.61 million shares outstanding. The public float is 79.61 million shares, elevated short interest at 23.90% of float. This equals 20.82 million shares. The short ratio is 8.86 days. Institutional investors hold 119.14% of the float. Insiders own 1.7%. ROYSTON IVOR holds 750.54 thousand shares, Metzger Michael A has 484.84 thousand shares and Podlesak Dennis has 191.76 thousand shares. Over the past six months, insider transactions show net selling. They sold 135.98 thousand shares across 9 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Syndax Pharmaceuticals has not generated any revenue. Returns are negative, with ROA at -34.16% and ROE at -37.78%.
On valuation metrics, Syndax Pharmaceuticals trades at a P/E of -7.80, P/S of 6.91 and P/B of 115.82. The current ratio is 6.77 and quick ratio is 6.44. Operationally, the company’s inventory turnover is 0.19 and cash conversion cycle is 1722.88 days. Debt-to-equity is 39.03, supported by a cash flow-to-debt ratio of -0.46.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Syndax Pharmaceuticals posted revenue of $0.00, down slightly from $0.00 in the prior quarter. Gross profit was - $12.00K (margin 0.00%). Operating income was - $229.95M (margin 0.0%). Net income was- $209.36M (EPS - $2.98).
The company ended the quarter with $577.58M in cash and short-term investments, a total debt of $1.64M, and net debt of - $293.76M. Total assets were $612.88M, with equity of $554.20M. Financials further reflected weakness, with operating cash flow of - $160.60M, free cash flow of - $160.60M, and capital expenditures of $0.00.

Price Forecast & Outlook

Our AI price prediction model suggests that Syndax Pharmaceuticals, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -17.86%, with price expected at $16.23 by August 19, 2026, within a range of $15.21 to $17.19 3-Month Outlook: Projected rise of 40.13%, reaching $27.69 by November 03, 2026, with a range of $27.29 to $28.04. 1-Year Outlook: Projected loss of -3.44%, with price at $19.08 by August 05, 2027, within a range of $17.61 to $20.75.

Key Takeaways

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) shares are flat -3.71% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Syndax Pharmaceuticals, Inc. trading at a premium to the broader market with a P/E of -7.8. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $43.13, suggesting 118.27% upside. Our AI forecast model points to short-term weakness (-17.86% over two weeks), a medium-term rise (40.13% over three months), and a longer-term loss (-3.44% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Syndax Pharmaceuticals, Inc. (SNDX) stock price?

Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) stock price is $19.76 in the last trading session. During the trading session, SNDX stock reached the peak price of $20.39 while $19.38 was the lowest point it dropped to. The percentage change in SNDX stock occurred in the recent session was -0.8% while the dollar amount for the price change in SNDX stock was - $0.16.

SNDX's industry and sector of operation?

The NASDAQ listed SNDX is part of Biotechnology industry that operates in the broader Healthcare sector. Syndax Pharmaceuticals, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of SNDX?

Sharon Klahre
Vice President of Investor Relations & Communications
Dr. Peter Ordentlich B.Sc., Ph.D.
Co-Founder & Chief Scientific Officer
Dr. Briggs W. Morrison M.D.
Pres, Head of R&D and Director
Dr. Ronald M. Evans Ph.D.
Co-Founder, Advisor and Chair of Scientific Advisory Board
Dr. Michael Downes Ph.D.
Co-Founder
Dr. Briggs W. Morrison M.D., Ph.D.
Pres, Head of R&D and Director
Mr. Michael A. Metzger M.B.A.
Chief Executive Officer & Director
Dr. Anjali Ganguli Ph.D.
Chief Bus. Officer
Mr. Keith Alan Goldan CPA
Chief Financial Officer, Treasurer & Chief Accounting Officer
Mr. Steve M. Sabus
Chief Commercial Officer
Mr. Luke J. Albrecht
Senior Vice President, Gen. Counsel & Sec.
Dr. Catherine Madigan M.D.
Chief Medical Officer
Mr. Alexander Nolte
Interim Chief Financial Officer, Principal Accounting Officer & Treasurer

How SNDX did perform over past 52-week?

SNDX's closing price is 63.31% higher than its 52-week low of $12.10 where as its distance from 52-week high of $25.59 is -22.78%.

How many employees does SNDX have?

Number of SNDX employees currently stands at 298.

Link for SNDX official website?

Official Website of SNDX is: https://www.syndax.com

How do I contact SNDX?

SNDX could be contacted at phone 781 419 1400 and can also be accessed through its website. SNDX operates from 730 Third Avenue, New York City, NY 10017, United States.

How many shares of SNDX are traded daily?

SNDX stock volume for the day was 1.48M shares. The average number of SNDX shares traded daily for last 3 months was 1.83M.

What is the market cap of SNDX currently?

The market value of SNDX currently stands at $1.75B with its latest stock price at $19.76 and 88.61M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	298
Beta	0.37
Sales or Revenue	$0.00
5Y Sales Change%	-1%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

SNDX Company Profile and Key Details

Syndax Pharmaceuticals

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Company Overview

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Dividend & Fair Value

Earnings & Analyst Outlook

Valuation Metrics

Key Takeaways

Price Forecast & Outlook